See more : Ypsomed Holding AG (YPSN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of ChemoCentryx, Inc. (CCXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChemoCentryx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Coloplast A/S (CLPBY) Income Statement Analysis – Financial Results
- Inrad Optics, Inc. (INRD) Income Statement Analysis – Financial Results
- Orell Füssli AG (OFN.SW) Income Statement Analysis – Financial Results
- CrowdFundMe S.p.A. (CFM.MI) Income Statement Analysis – Financial Results
- Labor Smart, Inc. (LTNC) Income Statement Analysis – Financial Results
ChemoCentryx, Inc. (CCXI)
About ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.22M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Cost of Revenue | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 31.92M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Gross Profit Ratio | 99.06% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 82.99M | 77.88M | 70.28M | 62.74M | 49.50M | 37.95M | 33.18M | 33.82M | 33.54M | 34.57M | 28.36M | 33.53M | 27.47M | 35.06M |
| General & Administrative | 0.00 | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.85M | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Other Expenses | 302.00K | 0.00 | -176.00K | 0.00 | 0.00 | -500.00K | 0.00 | 0.00 | 27.48M | 29.15M | 0.00 | 0.00 | 0.00 | -536.00K |
| Operating Expenses | 162.14M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Cost & Expenses | 162.45M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Interest Income | 859.00K | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 402.00K | 436.00K | 297.00K | 1.76M |
| Interest Expense | -2.70M | 2.64M | 2.15M | 1.22M | 4.00K | 0.00 | 0.00 | 24.00K | 59.00K | 794.00K | 734.00K | 81.00K | 76.00K | 129.00K |
| Depreciation & Amortization | 3.14M | 797.00K | 1.64M | 512.00K | 418.00K | 348.00K | 477.00K | 543.00K | 576.00K | 592.00K | 754.00K | 660.00K | 713.00K | 707.00K |
| EBITDA | -131.31M | -51.92M | -51.70M | -36.23M | 18.28M | -39.62M | -46.83M | -46.36M | -38.04M | -38.51M | -3.13M | -2.43M | 16.71M | -17.66M |
| EBITDA Ratio | -407.49% | -80.00% | -143.80% | -84.50% | 22.16% | -346.44% | 0.00% | 0.00% | -627.69% | -710.56% | -9.88% | -6.96% | 33.58% | -74.97% |
| Operating Income | -134.45M | -55.18M | -58.30M | -40.27M | 16.49M | -40.72M | -47.69M | -47.40M | -39.12M | -39.63M | -4.30M | -5.96M | 15.70M | -20.13M |
| Operating Income Ratio | -417.24% | -85.03% | -162.17% | -93.92% | 19.99% | -356.10% | 0.00% | 0.00% | -645.46% | -731.32% | -13.58% | -17.09% | 31.55% | -85.46% |
| Total Other Income/Expenses | -1.84M | -179.00K | 2.81M | 2.30M | 1.37M | 757.00K | 384.00K | 470.00K | 442.00K | -261.00K | -316.00K | 2.79M | 221.00K | 1.63M |
| Income Before Tax | -131.76M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.17M | 15.92M | -18.49M |
| Income Before Tax Ratio | -408.87% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -9.09% | 32.00% | -78.52% |
| Income Tax Expense | -2.70M | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 418.00K | -73.00K | 293.00K | -23.00K |
| Net Income | -129.06M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.10M | 15.62M | -18.47M |
| Net Income Ratio | -400.51% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -8.88% | 31.41% | -78.43% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 | 0.37 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| Weighted Avg Shares Out | 65.69M | 65.69M | 56.90M | 49.81M | 48.41M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
| Weighted Avg Shares Out (Dil) | 65.69M | 65.69M | 56.90M | 49.81M | 49.62M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
Is It Too Late to Buy ChemoCentryx Stock?
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-Associated Vasculitis
2 Super-Charged Growth Stocks to Buy Now
BZ Chart Of The Day: ChemoCentryx
CCXI Stock: Why It Increased Today
Source: https://incomestatements.info
Category: Stock Reports